194 related articles for article (PubMed ID: 19921098)
1. Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.
Demestre M; Herzberg J; Holtkamp N; Hagel C; Reuss D; Friedrich RE; Kluwe L; Von Deimling A; Mautner VF; Kurtz A
J Neurooncol; 2010 May; 98(1):11-9. PubMed ID: 19921098
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.
Wei J; Freytag M; Schober Y; Nockher WA; Mautner VF; Friedrich RE; Manley PW; Kluwe L; Kurtz A
PLoS One; 2014; 9(10):e107760. PubMed ID: 25340526
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
5. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
[TBL] [Abstract][Full Text] [Related]
6. Calcipotriol Enhances Efficacy of Imatinib and Nilotinib on Cells Derived from Plexiform Neurofibroma.
Zhao Y; Yan M; Mautner V; Smeets R; Gosau M; Kluwe L; Friedrich RE
Anticancer Res; 2021 Jul; 41(7):3293-3298. PubMed ID: 34230124
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.
Ohishi J; Aoki M; Nabeshima K; Suzumiya J; Takeuchi T; Ogose A; Hakozaki M; Yamashita Y; Iwasaki H
BMC Cancer; 2013 May; 13():224. PubMed ID: 23642185
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
10. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
[TBL] [Abstract][Full Text] [Related]
11. B-scan ultrasonographic monitoring of orthotopic xenografted plexiform neurofibroma in mice.
Gleiss J; Demestre M; Spyra M; Eschenhagen T; Hagel C; Mautner VF; Kluwe L; Friedrich RE
In Vivo; 2013; 27(6):723-7. PubMed ID: 24292574
[TBL] [Abstract][Full Text] [Related]
12. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
13. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.
Gobin B; Moriceau G; Ory B; Charrier C; Brion R; Blanchard F; Redini F; Heymann D
PLoS One; 2014; 9(3):e90795. PubMed ID: 24599309
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
17. Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate.
Kim Y; Fiel MI; Albanis E; Chou HI; Zhang W; Khitrov G; Friedman SL
Liver Int; 2012 Jul; 32(6):1008-17. PubMed ID: 22507133
[TBL] [Abstract][Full Text] [Related]
18. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
[TBL] [Abstract][Full Text] [Related]
19. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
